Role of gasdermin D in the pathological progression of liver diseases

Feiyan LI; Minggang WANG; Dewen MAO; Xiongbin GUI

doi:10.3969/j.issn.1001-5256.2023.03.035

Volume 39 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(3): 707-712

PDF( 1767 KB)

Role of gasdermin D in the pathological progression of liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.03.035

Feiyan LI^{1, 2a},
Minggang WANG^2a,
Dewen MAO^2b,
Xiongbin GUI^{2b
,
,
,}

1.
Graduate School, Guangxi University of Chinese Medicine, Nanning 530200, China
2a.
Department of Scientific Research, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China
2b.
Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

National Natural Science Foundation of China (82274434);

National Natural Science Foundation of China (81774236);

National Natural Science Foundation of China (81960841);

Guangxi Natural Science Foundation (2018GXNSFGA281002)

More Information

Corresponding author: GUI Xiongbin, Guixb2008@163.com (ORCID: 0000-0002-6417-497X)
Received Date: 2022-08-20
Accepted Date: 2022-10-16
Published Date: 2023-03-20

Abstract

Abstract

As a novel star molecule, gasdermin D (GSDMD) plays an important role in the amplification of immune inflammatory response and the process of pyroptosis. After being cleaved and activated by caspase-1, the N-terminal of GSDMD is rapidly released, which anchors on the cell membrane and forms pores, thereby leading to pyroptosis, accompanied by the release of a large amount of the strong proinflammatory factors IL-1β and IL-18. Acute/chronic liver inflammatory response and cell death are the common pathological features of liver diseases such as viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, autoimmune liver disease, liver failure, and hepatocellular carcinoma. This article summarizes the basic structural characteristics of GSDMD and elaborates on its important role in the pathological progression of various liver diseases. In addition, it is proposed that prevention and treatment strategies with GSDMD as a potential therapeutic target can provide new ideas for further studies on the clinical prevention and treatment of liver diseases.
- Liver Diseases,
- Gasdermin D,
- Pathologic Processes,
- Cell Death

FullText(HTML)

References(40)

References

[1]	FRICKER M, TOLKOVSKY AM, BORUTAITE V, et al. Neuronal cell death[J]. Physiol Rev, 2018, 98(2): 813-880. DOI: 10.1152/physrev.00011.2017.
[2]	KARMAKAR M, MINNS M, GREENBERG EN, et al. N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis[J]. Nat Commun, 2020, 11(1): 2212. DOI: 10.1038/s41467-020-16043-9.
[3]	FRANK D, VINCE JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk[J]. Cell Death Differ, 2019, 26(1): 99-114. DOI: 10.1038/s41418-018-0212-6.
[4]	YU P, ZHANG X, LIU N, et al. Pyroptosis: mechanisms and diseases[J]. Signal Transduct Target Ther, 2021, 6(1): 128. DOI: 10.1038/s41392-021-00507-5.
[5]	GAUL S, LESZCZYNSKA A, ALEGRE F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167. DOI: 10.1016/j.jhep.2020.07.041.
[6]	WANG K, SUN Q, ZHONG X, et al. Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis[J]. Cell, 2020, 180(5): 941-955. e20. DOI: 10.1016/j.cell.2020.02.002.
[7]	RODRÍGUEZ-ANTONIO I, LÓPEZ-SÁNCHEZ GN, URIBE M, et al. Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2021, 36(10): 2720-2727. DOI: 10.1111/jgh.15561.
[8]	XIAO WS, LE YY, ZENG SL, et al. Role of pyroptosis in liver diseases[J]. J Clin Hepatol, 2020, 36(12): 2847-2850. DOI: 10.3969/j.issn.1001-5256.2020.12.044. 肖伟松, 乐滢玉, 曾胜澜, 等. 细胞焦亡在肝脏疾病中的作用[J]. 临床肝胆病杂志, 2020, 36(12): 2847-2850. DOI: 10.3969/j.issn.1001-5256.2020.12.044.
[9]	ZENG DY, LI JM, LIN S, et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019[J]. J Hepatol, 2021, 75(3): 547-556. DOI: 10.1016/j.jhep.2021.04.035.
[10]	SETO MT, CHEUNG KW, HUNG I. Management of viral hepatitis A, C, D and E in pregnancy[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 68: 44-53. DOI: 10.1016/j.bpobgyn.2020.03.009.
[11]	CASTANEDA D, GONZALEZ AJ, ALOMARI M, et al. From hepatitis A to E: A critical review of viral hepatitis[J]. World J Gastroenterol, 2021, 27(16): 1691-1715. DOI: 10.3748/wjg.v27.i16.1691.
[12]	ZHENG M, WILLIAMS EP, MALIREDDI R, et al. Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection[J]. J Biol Chem, 2020, 295(41): 14040-14052. DOI: 10.1074/jbc.RA120.015036.
[13]	AVILA MA, DUFOUR JF, GERBES AL, et al. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting[J]. Gut, 2020, 69(4): 764-780. DOI: 10.1136/gutjnl-2019-319720.
[14]	SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 16. DOI: 10.1038/s41572-018-0014-7.
[15]	AXLEY PD, RICHARDSON CT, SINGAL AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease[J]. Clin Liver Dis, 2019, 23(1): 39-50. DOI: 10.1016/j.cld.2018.09.011.
[16]	CUI K, YAN G, XU C, et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice[J]. J Hepatol, 2015, 62(6): 1311-1318. DOI: 10.1016/j.jhep.2014.12.027.
[17]	KHANOVA E, WU R, WANG W, et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients[J]. Hepatology, 2018, 67(5): 1737-1753. DOI: 10.1002/hep.29645.
[18]	KUMAR S, DUAN Q, WU R, et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis[J]. Adv Drug Deliv Rev, 2021, 176: 113869. DOI: 10.1016/j.addr.2021.113869.
[19]	WANG XJ, MALHI H. Nonalcoholic fatty liver disease[J]. Ann Intern Med, 2018, 169(9): ITC65-ITC80. DOI: 10.7326/AITC201811060.
[20]	HUANG DQ, EL-SERAG HB, LOOMBA R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238. DOI: 10.1038/s41575-020-00381-6.
[21]	YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
[22]	MANNE V, HANDA P, KOWDLEY KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Clin Liver Dis, 2018, 22(1): 23-37. DOI: 10.1016/j.cld.2017.08.007.
[23]	WREE A, MCGEOUGH MD, PEÑA CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD[J]. J Mol Med (Berl), 2014, 92(10): 1069-1082. DOI: 10.1007/s00109-014-1170-1.
[24]	XU B, JIANG M, CHU Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice[J]. J Hepatol, 2018, 68(4): 773-782. DOI: 10.1016/j.jhep.2017.11.040.
[25]	CHEN S, CAI X, LIU Y, et al. The macrophage-associated microRNA-4715-3p/Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data[J]. Bioengineered, 2022, 13(5): 11740-11751. DOI: 10.1080/21655979.2022.2072602.
[26]	BURDETTE BE, ESPARZA AN, ZHU H, et al. Gasdermin D in pyroptosis[J]. Acta Pharm Sin B, 2021, 11(9): 2768-2782. DOI: 10.1016/j.apsb.2021.02.006.
[27]	FLOREANI A, de MARTIN S, SECCHI MF, et al. Extrahepatic autoimmunity in autoimmune liver disease[J]. Eur J Intern Med, 2019, 59: 1-7. DOI: 10.1016/j.ejim.2018.10.014.
[28]	SUCHER E, SUCHER R, GRADISTANAC T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies[J]. J Immunol Res, 2019, 2019: 9437043. DOI: 10.1155/2019/9437043.
[29]	LUAN J, ZHANG X, WANG S, et al. NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated conA-induced hepatitis[J]. Front Immunol, 2018, 9: 758. DOI: 10.3389/fimmu.2018.00758.
[30]	HUMPHRIES F, SHMUEL-GALIA L, KETELUT-CARNEIRO N, et al. Succination inactivates gasdermin D and blocks pyroptosis[J]. Science, 2020, 369(6511): 1633-1637. DOI: 10.1126/science.abb9818.
[31]	CASTILLO-DELA CRUZ P, WANEK AG, KUMAR P, et al. Intestinal IL-17R signaling constrains IL-18-Driven liver inflammation by the regulation of microbiome-derived products[J]. Cell Rep, 2019, 29(8): 2270-2283. e7. DOI: 10.1016/j.celrep.2019.10.042.
[32]	ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900.
[33]	KARVELLAS CJ, FRANCOZ C, WEISS E. Liver transplantation in acute-on-chronic liver failure[J]. Transplantation, 2021, 105(7): 1471-1481. DOI: 10.1097/TP.0000000000003550.
[34]	LI H, ZHAO XK, CHENG YJ, et al. Gasdermin D-mediated hepatocyte pyroptosis expands inflammatory responses that aggravate acute liver failure by upregulating monocyte chemotactic protein 1/CC chemokine receptor-2 to recruit macrophages[J]. World J Gastroenterol, 2019, 25(44): 6527-6540. DOI: 10.3748/wjg.v25.i44.6527.
[35]	WU YL. The role of Gasdermin D inhibitor necrosulfonamide in acute liver failure[D]. Fuzhou: Fujian Medical University, 2020. DOI: 10.27020/d.cnki.gfjyu.2020.001021" target="_blank">10.27020/d.cnki.gfjyu.2020.001021. 吴奕隆. Gasdermin D抑制剂necrosulfonamide在急性肝衰竭中作用[D]. 福州: 福建医科大学, 2020. DOI: 10.27020/d.cnki.gfjyu.2020.001021" target="_blank">10.27020/d.cnki.gfjyu.2020.001021.
[36]	YU LX, SCHWABE RF. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539. DOI: 10.1038/nrgastro.2017.72.
[37]	GALICIA-MORENO M, SILVA-GOMEZ JA, LUCANO-LANDEROS S, et al. Liver Cancer: therapeutic challenges and the importance of experimental models[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8837811. DOI: 10.1155/2021/8837811.
[38]	FU J, WANG H. Precision diagnosis and treatment of liver cancer in China[J]. Cancer Lett, 2018, 412: 283-288. DOI: 10.1016/j.canlet.2017.10.008.
[39]	CHEN YF, QI HY, WU FL. Euxanthone exhibits anti-proliferative and anti-invasive activities in hepatocellular carcinoma by inducing pyroptosis: preliminary results[J]. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8186-8196. DOI: 10.26355/eurrev_201812_16511.
[40]	LIU X, XIA S, ZHANG Z, et al. Channelling inflammation: gasdermins in physiology and disease[J]. Nat Rev Drug Discov, 2021, 20(5): 384-405. DOI: 10.1038/s41573-021-00154-z.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (518) PDF downloads(27)

Role of gasdermin D in the pathological progression of liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.03.035

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of gasdermin D in the pathological progression of liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.03.035

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content